Received Rs.2.84 Crore PO from M/s. Chowgule for satcom products; delivery by March 15, 2026; 24-month warranty.
2 Likes
Avantel Q2 results are out:
Summery:
Q2 FY26 results show sequential growth but YoY decline, reflecting order execution timing differences.
Margins remain solid despite ESOP-related expenses and expansion investments.
The company continues strengthening its balance sheet and investing in capacity expansion and R&D.
Balance Sheet Highlights (Standalone)
- Total Assets: ₹40,158.59 lakh (vs ₹29,775.65 lakh in Mar 2025)
- Equity Share Capital: ₹5,299.45 lakh
- Other Equity: ₹28,471.20 lakh
- Net Worth: ₹33,770.65 lakh
- Borrowings (Total): ₹3,919.01 lakh
Cash Flow (Standalone, H1 FY26)
- Operating Cash Flow: +₹682.37 lakh
- Investing Activities: (₹8,757.57 lakh) – major capex
- Financing Activities: +₹8,283.22 lakh – primarily from share issue proceeds
- Closing Cash: ₹366.37 lakh
Key Notes
- ESOP Expense: ₹177.57 lakh in Q2; ₹324.97 lakh for H1 FY26.
- 7,600 equity shares allotted to employees under the Avantel ESOP 2023 during the quarter.
- Segment Revenue (Consolidated):
- Communications & Signal Processing: ₹5,603.36 lakh
- Healthcare: ₹29.43 lakh (subsidiary iMeds Global Pvt. Ltd.)
- Subsidiary iMeds Global Pvt. Ltd. reported a loss of ₹190.4 lakh in Q2.
- No material auditor observations — Limited Review Reports express no adverse findings.
4 Likes
Mostly, things have moved as they mentioned, truly appreciate the management quality. The recent vigour seen in US space economy based companies is likely to start moving Avantel too (more of a speculation on my part). Still awaiting the ramp up of their medical business and the SDR orders.
2 Likes